Abstract:The human epidermal growth factor receptor-2-positive (HER2+) type is aggressive and has poor prognosis. Although anti-HER2 therapy alone or in combination with other treatment regimens showed significant improvement in survival outcomes, breast cancer patients are still suffering from tumor relapse and severe dose -limiting side effects. Thus, there is still an unmet challenge to develop effective therapeutic agents for HER2+ breast cancer treatment with minimized side effects. Herein, we produced a stimuli-responsive and tumor -targeted hyaluronic acid (HA) nanocomplex that combined HER2 blockade and chemotherapy for effective HER2+ breast cancer therapy. A hydrophobic NIR-II dye, IR1048, was covalently linked with HA to form a spherical HA-IR1048 nanoparticle (HINP), with Herceptin conjugated on the surface and paclitaxel (PTX) encapsulated inside. The fluorescent signals from the yielding Her-HINP/PTX are quenched originally, but a strong NIR-II signal is generated when HINP is degraded by the hyaluronidase that is overexpressed in breast tumors, thus allowing the tracking and visualization of Herceptin and PTX accumulation. Her-HINP/PTX peaked in HER2+ tumors at 24 h post injection as imaged by NIR-II fluorescent imaging. A significantly improved tumor growth inhibition effect was observed after five systemic treatments compared to single PTX (3.71 +/- 0.41 times) or Herceptin (5.98 +/- 0.51 times) treatment in a HER2-overexpressed breast cancer mouse model with prolonged survival. Collectively, the designed Her-HINP/PTX presents a new hyaluronidase-responsive and HER2 blockade nanoformulation that can visualize the accumulation of nanocomplexes and release drugs inside tumors for combined HER2+ breast cancer therapy with a great promise for translational study.Statement of significance: The high expressions of a protein called human epidermal growth factor receptor 2 (HER2) in breast tumors make this subtype of cancer aggressive. Currently, chemotherapy combined with a HER2 antibody, Herceptin, is a preferred approach for HER2-positive breast cancer therapy. However, these breast cancer patients still suffer from tumor relapse and severe side effects because various therapeutic agents have inherent different biodistributions, resulting in insufficient treatment effects and unfavorable normal organ uptake of these therapeutic agents. Herein, we produced a nanocomplex carrying both Herceptin and chemo-therapy drug to simultaneously deliver two drugs into tumors for efficient HER2+ tumor treatment with mini-mized side effects, providing new insights for designing a combined therapy strategy.

ATP/Hyals dually responsive core-shell hyaluronan/chitosan-based drug nanocarrier for potential application in breast cancer therapy

A polylysine/hyaluronan-based core-shell nanoparticle triggers drug delivery by ATP/hyaluronidase dual stimuli for inducing apoptosis of breast cancer cells

A Core/shell Stabilized Polysaccharide- Based Nanoparticle with Intracellular Environmentsensitive Drug Delivery for Breast Cancer Therapy

Hollow chitosan-silica nanospheres as pH-sensitive targeted delivery carriers in breast cancer therapy.

Hyaluronan Derivative Decorated Calcium Carbonate Nanoparticle As a Potential Platform for Breast Cancer Synergistic Therapy Via Blood Coagulation and Drug Delivery

Hyaluronic acid-based dual-responsive nanomicelles mediated mutually synergistic photothermal and molecular targeting therapies

Natural Polysaccharide-Incorporated Hydroxyapatite As Size-Changeable, Nuclear-Targeted Nanocarrier for Efficient Cancer Therapy

Hyaluronidase and pH Dual-Responsive Nanoparticles for Targeted Breast Cancer Stem Cells

A Dual-Responsive, Hyaluronic Acid Targeted Drug Delivery System Based on Hollow Mesoporous Silica Nanoparticles for Cancer Therapy.

A Hyaluronidase-Responsive Nanoparticle-Based Drug Delivery System for Targeting Colon Cancer Cells.

<p>Hyaluronic acid-modified mesoporous silica-coated superparamagnetic Fe<sub>3</sub>O<sub>4</sub> nanoparticles for targeted drug delivery</p>

Hyaluronic Acid–conjugated Silica Nanoparticles for Breast Cancer Therapy

Hyaluronic Acid Nanoparticles Based on a Conjugated Oligomer Photosensitizer: Target-Specific Two-Photon Imaging, Redox-Sensitive Drug Delivery, and Synergistic Chemo-Photodynamic Therapy

Self-assembled hyaluronic acid nanoparticles as a potential drug carrier for cancer therapy: synthesis, characterization, and in vivo biodistribution

Hyaluronic acid-modified mesoporous silica-coated superparamagnetic Fe 3 O 4 nanoparticles for targeted drug delivery.

Multifunctional composite nanoparticles based on hyaluronic acid-paclitaxel conjugates for enhanced cancer therapy

Hyaluronidase Responsive Second Near-Infrared Fluorescent Nanocomplex for Combined HER2 Blockade and Chemotherapy of HER2+ Breast Cancer

Biodegradable Self-Assembled Nanoparticles of Poly (D,l-Lactide-co-glycolide)/hyaluronic Acid Block Copolymers for Target Delivery of Docetaxel to Breast Cancer

Hyaluronan-based Theranostic Nanomicelles for Breast Cancer-Targeting and Anticancer Drug Delivery

Bioreducible Shell-Cross-Linked Hyaluronic Acid Nanoparticles for Tumor-Targeted Drug Delivery

Bovine Serum Albumin-Based and Dual-Responsive Targeted Hollow Mesoporous Silica Nanoparticles for Breast Cancer Therapy